TScan Therapeutics
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Lilly’s Omvoh shows improved outcomes in ulcerative colitis
The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Abivax shares positive late-stage results for obefazimod in ulcerative colitis
Inflammatory bowel disease affects nearly one in every 100 people in the US
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease